Flonoltinib for myelofibrosis symptoms and spleen size
Part of Blood & lymphatic clinical trials.
This trial tests a new oral medicine, flonoltinib maleate, to see if it can help reduce spleen size and improve symptoms in people with myelofibrosis, a type of blood disorder. The study enrolls patients who have not responded to other treatments or have not had JAK inhibitor therapy (or only briefly).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have primary myelofibrosis, or post-polycythemia vera or post-essential thrombocythemia myelofibrosis.
- You have an enlarged spleen (can be felt 5 cm below the rib cage or, due to body size, confirmed by scan to be at least 450 cc).
- You have at least 2 symptoms like fatigue or bone pain that are moderate to severe, or an overall symptom burden that is high.
- Your blood counts are not too low: platelets above 50, ANC above 1.0, and hemoglobin above 60 g/L.
- You have heart, liver, and kidney function within acceptable limits and do not have to wait for a stem cell transplant in the next 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying the effectiveness of momelotinib, a JAK inhibitor, for people with myelofibrosis who have an enlarged spleen. It aims to see how well the drug works in real-world practice.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests a higher dose of ruxolitinib before a stem cell transplant for people with myelofibrosis who have an enlarged spleen. It aims to see if this approach helps the transplant work better.
This trial tests an oral drug called tasquinimod for people with myelofibrosis that no longer responds to or cannot take a JAK inhibitor. The goal is to see if tasquinimod can help shrink an enlarged spleen and improve symptoms.
This trial tests a combination of two drugs, selinexor and pacritinib, for people with myelofibrosis who have not had previous JAK inhibitor treatment and have low red blood cells (anemia) or low platelets. The goal is to see if these drugs can help improve symptoms and reduce spleen size while being safe for patients with cytopenias.
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.